Latest News on SPRY

Financial News Based On Company


Advertisement
Advertisement

Why Is SELLAS Life Sciences (NASDAQ:SLS) Sliding 13.98% While Evolent Health (NYSE:EVH), ARS Pharmaceuticals (NASDAQ:SPRY) and PepGen (NASDAQ:PEPG) Trade Unevenly?

https://kalkine.ca/news/healthcare/why-is-sellas-life-sciences-nasdaqsls-sliding-1398-while-evolent-health-nyseevh-ars-pharmaceuticals-nasdaqspry-and-pepgen-nasdaqpepg-trade-unevenly
SELLAS Life Sciences (NASDAQ:SLS) shares dropped 13.98% following a proposed USD 150 million public offering, which came two days after its Phase 3 REGAL study met its primary survival goal. Meanwhile, PepGen (NASDAQ:PEPG) gained 8.82% but remained below its offering price, ARS Pharmaceuticals (NASDAQ:SPRY) fell 7.62% without a clear catalyst, and Evolent Health (NYSE:EVH) slipped 5.47% despite revenue growth, as its medical expense ratio increased. The article highlights that while SELLAS's decline is linked to its offering, the other three companies' stock movements lack immediate announced triggers, with financing challenges being a common theme.

Form 144 ARS PHARMACEUTICALS For: 9 November By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-ars-pharmaceuticals-for-9-november-93CH-4944673
This article announces the filing of Form 144 for ARS PHARMACEUTICALS on November 9. The content is brief and primarily serves as a notification of the regulatory filing, without providing further details or analysis within the main body.

Officer Eric Karas proposes a $402K share sale at ARS Pharmaceuticals (SPRY).

https://www.stocktitan.net/sec-filings/SPRY/144-ars-pharmaceuticals-inc-sec-filing-b33ace086567.html
Eric Karas, an officer at ARS Pharmaceuticals (SPRY), has filed a Form 144 proposing to sell 139,588 common shares valued at approximately $402,362, with an approximate sale date of November 9, 2026. The filing also details several prior share sales by Karas between September 11 and October 30, 2026. The proposed sale stems from a stock option exercise.

ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results

https://www.benzinga.com/analyst-stock-ratings/price-target/26/11/62974223/ars-pharmaceuticals-analysts-cut-their-forecasts-after-downbeat-q3-results
ARS Pharmaceuticals (NASDAQ: SPRY) reported weaker-than-expected Q3 results, missing analyst consensus for both losses per share and quarterly sales. Following the announcement, analysts from Raymond James and Cantor Fitzgerald downgraded the stock or lowered their price targets, despite the company's CEO highlighting progress on corporate priorities including market share growth, financial discipline, and platform expansion. ARS Pharmaceuticals shares still saw a jump in pre-market trading.

ARS Pharmaceuticals, Inc. (SPRY) Stock Price, News, Quote & History

https://ca.finance.yahoo.com/quote/SPRY/
This Yahoo Finance page provides a detailed overview of ARS Pharmaceuticals, Inc. (SPRY), including its current stock price, recent news, historical data, and analyst insights. The company, which develops treatments for severe allergic reactions, saw its stock price at $2.7900 with a 5.28% increase at close on November 6, 2026. The page also features performance overview, earnings trends, valuation measures, and financial highlights.
Advertisement

Raymond James downgrades ARS Pharmaceuticals stock rating on weak sales

https://ca.investing.com/news/stock-market-news/raymond-james-downgrades-ars-pharmaceuticals-stock-rating-on-weak-sales-93CH-4938287
Raymond James downgraded ARS Pharmaceuticals (NASDAQ: SPRY) from Strong Buy to Outperform, lowering its price target due to weaker-than-expected neffy sales in the third quarter. The stock's price target was reduced from $28.00 to $17.00, reflecting concerns about the commercial trajectory and the need for new management to implement its strategy. The company also reported a wider loss per share and lower revenue than analysts predicted, despite increased demand for its neffy product.

ARS Pharmaceuticals Inc (SPRY) Q3 2026 Earnings Call Highlights: neffy Market Share Tops 5% as ...

https://uk.finance.yahoo.com/news/ars-pharmaceuticals-inc-spry-q3-111646220.html
ARS Pharmaceuticals (SPRY) reported Q3 2026 total revenue of $37.7 million, with neffy US net product revenue at $33.4 million and its US market share surpassing 5%. The company saw a 42% year-over-year increase in neffy end-user demand and reduced SG&A expenses significantly, remaining on track for cash flow breakeven by year-end 2027. Despite challenges like prior authorization requirements and inventory fluctuations, ARS Pharmaceuticals is progressing with its commercial strategy and pipeline candidates.

Raymond James downgrades ARS Pharmaceuticals stock rating on weak sales

https://www.investing.com/news/analyst-ratings/raymond-james-downgrades-ars-pharmaceuticals-stock-rating-on-weak-sales-93CH-5007282
Raymond James has downgraded ARS Pharmaceuticals (NASDAQ:SPRY) from Strong Buy to Outperform and lowered its price target due to weaker-than-expected neffy sales in Q3 2026. The stock is currently trading near its 52-week low, but InvestingPro analysis suggests it is undervalued. The firm expects ARS Pharmaceuticals' new management team will need time to implement its revised commercial strategy, which aims for cash flow break-even by the end of 2027.

ARS Pharma (SPRY) Q3 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/markets-news/motley/8701437/ars-pharma-spry-q3-2026-earnings-call-transcript/
ARS Pharma (SPRY) reported its Q3 2026 financial and operational results, including $37.7 million in total revenue and reaffirming its goal to achieve cash flow breakeven by the end of 2027. The company's neffy nasal spray saw increased market share, especially in targeted accounts, driven by a 42% rise in end-user demand. ARS Pharma is also advancing its ARS-2 pipeline candidate for chronic spontaneous urticaria, with interim Phase 2b data expected in early 2027.

ARS Pharmaceuticals, Inc. (SPRY) Misses Q3 EPS by 6c

https://www.streetinsider.com/Earnings/ARS+Pharmaceuticals%2C+Inc.+%28SPRY%29+Misses+Q3+EPS+by+6c/27300535.html
ARS Pharmaceuticals, Inc. (SPRY) reported its Q3 earnings, missing analyst estimates. The company posted an EPS of ($0.36), which was $0.06 worse than the anticipated ($0.30). Additionally, its revenue for the quarter came in at $37.7 million, falling short of the consensus estimate of $41.99 million.
Advertisement

ARS Pharmaceuticals Q3 2026 Earnings Call Transcript

https://www.benzinga.com/news/26/11/62957786/ars-pharmaceuticals-q3-2026-earnings-call-transcript
ARS Pharmaceuticals reported Q3 2026 revenue of $37.7 million, with NEFFY's U.S. net product revenue increasing 42% year-over-year. The company is focused on disrupting the epinephrine market with NEFFY, achieving cash flow breakeven by 2027, and expanding its platform to treat chronic spontaneous urticaria (CSU) with ARS2. Operating expenses were reduced by over 40% in SG&A, and the Phase 2b trial for ARS2 is on track for interim data in Q1 2027, aiming for the first FDA-approved on-demand treatment for CSU flares.

ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates

https://finance.yahoo.com/markets/stocks/articles/ars-pharmaceuticals-inc-spry-reports-214513372.html
ARS Pharmaceuticals, Inc. (SPRY) reported a Q3 loss of $0.36 per share, missing the Zacks Consensus Estimate of $0.34, and also fell short of revenue estimates with $37.71 million against an expected $42.69 million. The company's shares have significantly underperformed the S&P 500 year-to-date, leading to a Zacks Rank #4 (Sell) outlook.

SPRY: ARS Pharmaceuticals Inc. filed SEC Form 8-K: Results of...

https://www.quantisnow.com/insight/ars-pharmaceuticals-inc-filed-sec-form-8-k-results-of-operations-6776012
ARS Pharmaceuticals Inc. reported Q3 2026 revenue of $37.7 million, with neffy U.S. net product revenue at $33.4 million. The company's net loss for the quarter was $35.6 million, a reduction from the prior year, and it reaffirmed its goal of achieving cash flow breakeven by the end of 2027. Despite narrowing losses and increased market share for neffy, the company continues to operate at a net loss.

ARS Pharma Reports Business Highlights and Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/11/05/3396994/0/en/ars-pharma-reports-business-highlights-and-third-quarter-2026-financial-results.html
ARS Pharmaceuticals reported strong third-quarter 2026 financial results, including total revenue of $37.7 million and neffy U.S. market share reaching 5% overall. The company is advancing its three-pillar growth strategy, strengthening its leadership team with key appointments, and progressing its ARS-2 pipeline for chronic spontaneous urticaria. ARS Pharma remains on track to achieve cash flow breakeven by year-end 2027.

80,000 shares are proposed for sale by ARS Pharmaceuticals (SPRY) officer Eric Karas.

https://www.stocktitan.net/sec-filings/SPRY/144-ars-pharmaceuticals-inc-sec-filing-7878c1185de6.html
ARS Pharmaceuticals (SPRY) officer Eric Karas has filed a Form 144 proposing to sell 80,000 common shares with an aggregate market value of $270,272.00, with an approximate sale date of October 30, 2026. The shares were acquired through a stock option exercise on the same date. The filing also details prior sales by Karas, including 100,000 shares on October 19, 2026, and other dates in September and October.
Advertisement

ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

https://finance.yahoo.com/markets/stocks/articles/ars-pharmaceuticals-inc-spry-may-130007941.html
ARS Pharmaceuticals (SPRY) is projected to report a year-over-year increase in earnings and higher revenues for the quarter ended September 2026, with an expected loss of $0.34 per share and revenues of $42.69 million. Despite this outlook, analysts have revised EPS estimates lower, resulting in a negative Earnings ESP of -19.40% and a Zacks Rank of #4, making a positive earnings surprise difficult to predict. The company has missed consensus EPS estimates in the last four quarters.

ARS Pharma to Report Third Quarter 2026 Financial Results

https://www.streetinsider.com/Globe+Newswire/ARS+Pharma+to+Report+Third+Quarter+2026+Financial+Results/27248932.html
ARS Pharmaceuticals, Inc. announced it will host a conference call and webcast on Thursday, November 5, 2026, to discuss its third quarter 2026 financial results. The call will be held at 1:30 p.m. PT / 4:30 p.m. ET. ARS Pharma is a biopharmaceutical company focused on treatments for severe allergic reactions, commercializing neffy® (epinephrine nasal spray) and developing ARS-2 for chronic spontaneous urticaria.

ARS Pharma to Report Third Quarter 2026 Financial Results

https://investingnews.com/ars-pharma-to-report-third-quarter-2026-financial-results/
ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) announced it will host a conference call and webcast on Thursday, November 5, 2026, to discuss its third quarter 2026 financial results. The company is a commercial biopharmaceutical firm focused on treatments for severe allergic reactions, notably neffy® (epinephrine nasal spray). A replay of the webcast will be available for 30 days following the event.

A webcast on ARS Pharmaceuticals' third-quarter results will have a 30-day replay after Nov. 5.

https://www.stocktitan.net/news/SPRY/ars-pharma-to-report-third-quarter-2026-financial-zspslulkonyf.html
ARS Pharmaceuticals (SPRY) will host a conference call and webcast on November 5, 2026, to discuss its third-quarter 2026 financial results. The call is scheduled for 1:30 p.m. PT / 4:30 p.m. ET, with a 30-day replay of the webcast and slides available on the company's website. The company specializes in treatments for severe allergic reactions, including its FDA and EMA-approved epinephrine nasal spray, neffy.

ARS Pharma to Report Third Quarter 2026 Financial Results

https://www.globenewswire.com/news-release/2026/10/28/3390713/0/en/ars-pharma-to-report-third-quarter-2026-financial-results.html
ARS Pharmaceuticals, Inc. announced it will host a conference call and webcast on Thursday, November 5, 2026, to discuss its third-quarter 2026 financial results. The company is a commercial biopharmaceutical firm focused on developing and commercializing treatments for severe allergic reactions, including its FDA and EMA-approved needle-free epinephrine nasal spray, neffy®.
Advertisement

ARS Pharmaceuticals Inc (SPRY) sentiment score, message volume, participation score and buzz level

https://stocktwits.com/symbol/SPRY/sentiment
This article provides an overview of ARS Pharmaceuticals Inc (SPRY) stock, focusing on its sentiment score, message volume, and participation ratio. It explains how these metrics indicate user sentiment (bearish or bullish), the amount of discussion, and the number of unique accounts posting about the stock over various timeframes (24 hours, 1 week, 1 month, 3 months, 6 months, 1 year). The data presented shows "N/A" for the last score across all metrics, suggesting no recent data was available at the time of publication.

ARS Pharmaceuticals, Inc. Estimates – NASDAQ:SPRY

https://www.tradingview.com/symbols/NASDAQ-SPRY/financials-estimates/
This article provides an overview of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) financial data and analyst estimates available on TradingView. It highlights sections for exploring reported financial data, comparing actual results with estimates, and visualizing trends across income statements, balance sheets, cash flow statements, and valuation metrics. The content emphasizes that it is not investment advice and encourages users to conduct their own research.

Form 144 ARS PHARMACEUTICALS For: 20 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-144-ars-pharmaceuticals-for-20-october-93CH-4889762
This article from Investing.com announces the filing of Form 144 for ARS Pharmaceuticals on October 20, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity or significant stock transactions. The article provides only this brief announcement and does not offer further details or analysis regarding the filing.

Form 4 ARS Pharmaceuticals Inc For: 12 October By Investing.com

https://ca.investing.com/news/stock-market-news/form-4-ars-pharmaceuticals-inc-for-12-october-93CH-4875501
This article from Investing.com reports on a Form 4 filing for ARS Pharmaceuticals Inc., dated October 12. Form 4 filings are typically used to report changes in beneficial ownership of company securities by insiders. The article provides the basic announcement without further details on the filing's content.

Form 4 ARS Pharmaceuticals Inc For: 12 October By Investing.com

https://za.investing.com/news/stock-market-news/form-4-ars-pharmaceuticals-inc-for-12-october-93CH-4499366
This article from Investing.com reports on a Form 4 filing by ARS Pharmaceuticals Inc. The filing was made on October 12, 2026. The article itself is a brief announcement about this SEC filing.
Advertisement

ARS Pharmaceuticals (SPRY) Short Interest & Short Float | Updated Oct 2026 $SPRY

https://www.marketbeat.com/stocks/NASDAQ/SPRY/short-interest/
ARS Pharmaceuticals (SPRY) reported a short interest of 21.19 million shares as of September 30, 2026, which represents 32.19% of its public float and a decrease of 8.16% from the prior month. The short interest ratio is 16.1 days to cover, indicating strong pessimism. The article details historical short interest data and explains what various short interest metrics mean for investors.

A stock option with a $4.12 exercise price goes to ARS Pharmaceuticals (SPRY) CEO Donn Casale.

https://www.stocktitan.net/sec-filings/SPRY/form-4-ars-pharmaceuticals-inc-insider-trading-activity-136a7d75a96b.html
ARS Pharmaceuticals' President and CEO, Donn Casale, was granted a stock option for 1,036,923 shares with an exercise price of $4.12 per share. A quarter of these shares will vest on July 7, 2027, with the remainder vesting monthly over the subsequent three years. The option is set to expire on September 30, 2036.

SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

https://www.midfloridanewspapers.com/ap/business/spry-final-deadline-alert-faruqi-faruqi-llp-reminds-ars-pharmaceuticals-investors-of-securities-class-action/article_8511431e-da40-5c28-9154-a0447793ecff.html
Faruqi & Faruqi, LLP is reminding investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) about the October 5, 2026 deadline to seek lead plaintiff status in a federal securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made false or misleading statements regarding the timeline for expanded insurance coverage of its product, neffy, through CVS Caremark. The company's stock price dropped significantly after it announced that no new commercial formulary additions for neffy would occur in July 2026, and CVS Caremark reserved its decision until January 2027.

Levi & Korsinsky Notifies ARS Pharmaceuticals, Inc. (SPRY) Shareholders of Class Action Lawsuit and October 5, 2026 Deadline

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/levi-and-korsinsky-notifies-ars-pharmaceuticals-inc.-spry-shareh-1233381
Levi & Korsinsky, LLP has announced a securities class action lawsuit against ARS Pharmaceuticals, Inc. (SPRY) for investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding expanded insurance coverage for neffy through CVS Caremark, which caused a significant stock price decline when the lack of coverage was revealed. Shareholders are encouraged to contact Levi & Korsinsky to learn about their rights to seek recovery.

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law

https://www.businesswire.com/news/home/20261005313580/en/SPRY-Investors-Have-Opportunity-to-Lead-ARS-Pharmaceuticals-Inc.-Securities-Fraud-Lawsuit-with-SBS-Law
Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for alleged securities fraud. The lawsuit claims ARS made false and misleading statements regarding the timeline for insurance coverage of its drug neffy, which impacted its commercialization and led to investor damages. Shareholders who purchased SPRY shares between March 9, 2026, and June 24, 2026, are encouraged to contact SBS before the October 5, 2026 deadline to potentially serve as lead plaintiff.
Advertisement

Class Action Lawsuit Filed: ARS Pharmaceuticals, Inc. (SPRY) - Join by October 5, 2026 - Contact Levi & Korsinsky

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/class-action-lawsuit-filed-ars-pharmaceuticals-inc.-spry-join-by-1232659
A class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on behalf of investors who suffered losses due to alleged securities fraud between March 9, 2026, and June 24, 2026. The lawsuit claims the company made misleading statements regarding expanded insurance coverage for its product neffy through CVS Caremark, which caused a significant stock price drop when the lack of coverage was revealed. Investors are encouraged to join the lawsuit by October 5, 2026, by contacting Levi & Korsinsky, LLP.

Lost Money on ARS Pharmaceuticals, Inc. (SPRY)? Urged to Join Class Action Before October 5, 2026 - Contact Levi & Korsinsky

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/lost-money-on-ars-pharmaceuticals-inc.-spry-urged-to-join-class-1232434
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on behalf of investors who suffered losses due to alleged securities fraud between March 9, 2026, and June 24, 2026. The lawsuit claims that the company made misleading statements regarding expanded insurance coverage for its product, neffy, through CVS Caremark. Investors are urged to join the class action before October 5, 2026, to explore potential recovery.

ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY

https://www.globenewswire.com/news-release/2026/10/02/3373984/0/en/ars-pharmaceuticals-deadline-rosen-trusted-investor-counsel-encourages-ars-pharmaceuticals-inc-investors-to-secure-counsel-before-important-october-5-deadline-in-securities-class-a.html
The Rosen Law Firm is reminding investors of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) who purchased securities between March 9, 2026, and June 24, 2026, about the October 5, 2026, lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the expected timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, through CVS Caremark, causing investors to purchase securities at inflated prices. Investors are encouraged to contact the firm to join the class action and learn about their potential compensation.

ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit

https://www.prnewswire.com/news-releases/ars-pharmaceuticals-deadline-spry-investors-have-opportunity-to-lead-ars-pharmaceuticals-inc-securities-fraud-lawsuit-302897436.html
The Rosen Law Firm reminds purchasers of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) securities between March 9, 2026, and June 24, 2026, of the October 5, 2026, lead plaintiff deadline for a securities fraud lawsuit. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the expanded insurance coverage timeline for its epinephrine nasal spray, neffy, with CVS Caremark, causing investors to purchase shares at inflated prices. Investors are encouraged to contact the firm to join the class action.

ARS PHARMACEUTICALS DEADLINE MONDAY: Bragar Eagel & Squire,

https://www.globenewswire.com/news-release/2026/10/02/3373979/0/en/ars-pharmaceuticals-deadline-monday-bragar-eagel-squire-p-c-reminds-ars-pharmaceuticals-investors-to-contact-the-firm-before-october-5th-seeking-lead-plaintiff-role.html
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against ARS Pharmaceuticals (NASDAQ:SPRY) for investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals failed to disclose risks regarding the expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Investors have until October 5, 2026, to apply to be appointed as lead plaintiff.
Advertisement

Shareholders of ARS Pharmaceuticals, Inc. (SPRY): Protect Your Rights Before October 5, 2026 - Contact Levi & Korsinsky

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/shareholders-of-ars-pharmaceuticals-inc.-spry-protect-your-right-1230534
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on behalf of investors who suffered losses due to alleged securities fraud between March 9, 2026, and June 24, 2026. The lawsuit claims that ARS Pharmaceuticals made misleading statements regarding expanded insurance coverage for neffy through CVS Caremark, which led to a significant stock price decline when the lack of coverage was revealed. Investors are encouraged to contact the firm to learn about their rights to potentially recover losses before October 5, 2026.

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026

https://www.morningstar.com/news/pr-newswire/20261001ny59581/spry-shareholder-notice-faruqi-faruqi-llp-reminds-ars-pharmaceuticals-investors-of-securities-class-action-lawsuit-deadline-on-october-5-2026
Faruqi & Faruqi, LLP has issued a shareholder notice reminding ARS Pharmaceuticals investors of the securities class action lawsuit deadline on October 5, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the expanded insurance coverage for neffy through CVS Caremark, which led to a significant stock price drop. Investors who suffered losses between March 9, 2026, and June 24, 2026, are encouraged to contact the firm to discuss their legal options and potentially seek the role of lead plaintiff.

Officer Eric Karas proposes selling 100,000 shares of ARS Pharmaceuticals (SPRY).

https://www.stocktitan.net/sec-filings/SPRY/144-ars-pharmaceuticals-inc-sec-filing-f2b3832fb7df.html
Eric Karas, an officer at ARS Pharmaceuticals (SPRY), has proposed selling 100,000 common shares with an approximate sale date of October 1, 2026, valued at $426,096.77. The notice also reveals prior sales by Karas including 100,000 shares sold on September 30, 2026, for $431,560.00 and 14,064 shares sold on September 11, 2026, for $69,761.66. These proposed and past transactions are detailed in a Form 144 SEC filing.

Eric Karas proposes selling 100,000 ARS Pharmaceuticals (SPRY) shares after a $69.8K September sale.

https://www.stocktitan.net/sec-filings/SPRY/144-ars-pharmaceuticals-inc-sec-filing-9c7aef3d775d.html
Eric Karas, an officer at ARS Pharmaceuticals (SPRY), has proposed selling 100,000 common shares valued at $431,560. This proposed sale stems from a stock option exercise dated September 30, 2026. Karas also reported a previous sale of 14,064 common shares on September 11, 2026, which generated $69,761.66.

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY

https://www.prnewswire.com/news-releases/levi--korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-october-5-2026-in-ars-pharmaceuticals-inc-lawsuit---spry-302894578.html
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) for shareholders who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the timeline for CVS Caremark formulary coverage of its drug, neffy, leading to a significant stock price drop when the July 1, 2026, coverage date was missed. Investors who suffered losses have until October 5, 2026, to seek appointment as lead plaintiff.
Advertisement

Did You Lose Money on ARS Pharmaceuticals, Inc. (SPRY)? Levi & Korsinsky Urges Investors to Act Before October 5, 2026

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/did-you-lose-money-on-ars-pharmaceuticals-inc.-spry-levi-and-kor-1228951
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on behalf of investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that the company made misleading statements regarding the expanded insurance coverage timeline for its product neffy through CVS Caremark, leading to a significant stock price decline when the lack of coverage was revealed. Investors who suffered losses are urged to contact Levi & Korsinsky before October 5, 2026, to explore potential recovery.

Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors

https://www.globenewswire.com/news-release/2026/09/29/3370926/0/en/portnoy-law-firm-announces-class-action-on-behalf-of-ars-pharmaceuticals-inc-investors.html
The Portnoy Law Firm has announced a class action lawsuit on behalf of investors in ARS Pharmaceuticals, Inc. (NASDAQ: SPRY). The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the timeline for expanded insurance coverage of its drug neffy with CVS Caremark. Following the announcement on June 24, 2026, that CVS Caremark had delayed its decision until January 2027, ARS Pharmaceuticals' stock price declined by nearly 24%.

ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR

https://www.globenewswire.com/news-release/2026/09/29/3370354/673/en/ars-pharmaceuticals-deadline-rosen-skilled-investor-counsel-encourages-ars-pharmaceuticals-inc-investors-to-secure-counsel-before-important-october-5-deadline-in-securities-class-a.html
The Rosen Law Firm is reminding investors of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) about the October 5, 2026 lead plaintiff deadline for a securities class action lawsuit. The lawsuit alleges that ARS Pharmaceuticals made false and misleading statements regarding the expected timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Investors who purchased securities during the class period (March 9, 2026, and June 24, 2026) are encouraged to contact the Rosen Law Firm for potential compensation.

Lost Money on ARS Pharmaceuticals, Inc. (SPRY)? Contact Levi & Korsinsky Before October 5, 2026 to Join Class Action

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/lost-money-on-ars-pharmaceuticals-inc.-spry-contact-levi-and-kor-1227946
Levi & Korsinsky, LLP has filed a securities class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit claims that ARS Pharmaceuticals made false and misleading statements regarding expanded insurance coverage for neffy through CVS Caremark. Following the announcement that coverage would not be expanded by the expected deadline, the company's stock price dropped significantly.

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals

https://www.globenewswire.com/news-release/2026/09/28/3370123/9788/en/bronstein-gewirtz-grossman-llc-urges-ars-pharmaceuticals-inc-investors-to-act-class-action-filed-alleging-investor-harm.html
Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) and its officers, alleging violations of federal securities laws. The lawsuit claims that ARS Pharmaceuticals made misleading statements and concealed material facts regarding the expected timeline for expanded insurance coverage for neffy through CVS Caremark, harming investors who purchased securities between March 9, 2026, and June 24, 2026. Investors are urged to join the class action by October 5, 2026, to potentially recover damages.
Advertisement

Faruqi & Faruqi, LLP Urges ARS Pharmaceuticals (SPRY) Investors to Seek Counsel Before the October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action

https://www.newsfilecorp.com/release/316043/Faruqi-Faruqi-LLP-Urges-ARS-Pharmaceuticals-SPRY-Investors-to-Seek-Counsel-Before-the-October-5-2026-Lead-Plaintiff-Deadline-in-the-Securities-Class-Action
Faruqi & Faruqi, LLP is urging investors of ARS Pharmaceuticals (NASDAQ: SPRY) to seek legal counsel regarding a securities class action lawsuit before the October 5, 2026, lead plaintiff deadline. The lawsuit alleges that ARS Pharmaceuticals and its executives made misleading statements concerning the timeline for expanded insurance coverage of neffy through CVS Caremark, leading to a 24% stock drop on June 25, 2026. Investors who purchased ARS shares between March 9, 2026, and June 24, 2026, are encouraged to contact the firm to discuss their options.

Kaplan Fox & Kilsheimer LLP Alerts ARS Pharmaceuticals Inc. (NASD

https://natlawreview.com/press-releases/kaplan-fox-kilsheimer-llp-alerts-ars-pharmaceuticals-inc-nasdaq-spry
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against ARS Pharmaceuticals Inc. (NASDAQ: SPRY) for investors who purchased securities between March 9, 2026, and June 24, 2026. The lawsuit alleges that the company's stock fell significantly after it disclosed that no new commercial formulary additions or coverage decisions had been issued for its drug, neffy. Investors are encouraged to join the case by October 5, 2026, to serve as a lead plaintiff.

Robbins LLP Reminds SPRY Stockholders of the Pending October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action Against ARS Pharmaceuticals Inc.

https://www.globenewswire.com/news-release/2026/09/25/3369363/0/en/robbins-llp-reminds-spry-stockholders-of-the-pending-october-5-2026-lead-plaintiff-deadline-in-the-securities-class-action-against-ars-pharmaceuticals-inc.html
Robbins LLP is reminding stockholders of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) about a securities class action lawsuit filed against the company. The lawsuit alleges that ARS Pharmaceuticals made misleading statements regarding the timeline for expanded insurance coverage for its epinephrine nasal spray, neffy, with CVS Caremark. Investors who purchased SPRY securities between March 9, 2026, and June 24, 2026, and suffered losses, have until October 5, 2026, to seek appointment as lead plaintiff.

Class Action Filed Against ARS Pharmaceuticals, Inc. (SPRY) Over Securities Violations - Contact Levi & Korsinsky Today

https://www.accessnewswire.com/newsroom/en/business-and-professional-services/class-action-filed-against-ars-pharmaceuticals-inc.-spry-over-se-1227439
A class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) on behalf of investors who suffered losses due to alleged securities fraud. The lawsuit claims that the company made misleading statements regarding the timeline for expanded insurance coverage of its product, neffy, through CVS Caremark. Following the announcement that this coverage was delayed, ARS Pharmaceuticals' stock price declined significantly.

Robbins LLP Reminds SPRY Stockholders of the Pending October 5, 2026 Lead Plaintiff Deadline in the Securities Class Action Against ARS Pharmaceuticals Inc.

https://www.globenewswire.com/news-release/2026/09/25/3369363/32719/en/robbins-llp-reminds-spry-stockholders-of-the-pending-october-5-2026-lead-plaintiff-deadline-in-the-securities-class-action-against-ars-pharmaceuticals-inc.html
Robbins LLP is reminding investors of ARS Pharmaceuticals Inc. (NASDAQ: SPRY) about a pending securities class action lawsuit, with a lead plaintiff deadline of October 5, 2026. The lawsuit alleges that ARS Pharmaceuticals misled investors regarding the expected timeline for expanded insurance coverage of its epinephrine nasal spray, neffy, with CVS Caremark. The company's stock declined significantly after it announced that the expanded coverage would not be in place by the anticipated July 1, 2026, deadline.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement